THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.14] ID: TIP-MED-000198

Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism)

Active Ingredient / Scientific Identity: Calcitriol & Alfacalcidol • Class: Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H)

⚖️ Compare Profile
Generic / Entity NameCalcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism) ([10.14])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassActive 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor A
Available Dosage FormsSoftgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacal
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Calcitriol & Alfacalcidol (Active Vitamin D Metabolites for CKD-MBD & Hypoparathyroidism) (TIP-MED-000198, Reference Code [10.14]) is classified under Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10) as a Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.14], p. 133): Calcitriol: Rocaltrol (Abbott), Gemsoline (Macmillon), Calcitrol (Cadila). Alfacalcidol: One-Alpha (Leo), Alpha D3 (Panacea) — Strengths & Dosage Forms: Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
Representative Indian Market Examples (Edition 2.7 Ch 10 [10.14], p. 133): Calcitriol: Rocaltrol (Abbott), Gemsoline (Macmillon), Calcitrol (Cadila). Alfacalcidol: One-Alpha (Leo), Alpha D3 (Panacea) — Strengths & Dosage Forms: Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
Dosage Forms & Available Strengths:
Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — CKD-MBD & Electrolyte Binders/Buffers (Ch 10): clinical efficacy is mediated via Active 1,25-Dihydroxycholecalciferol & 1-Alpha-Hydroxycholecalciferol Vitamin D Receptor Agonists (Schedule H) for Secondary hyperparathyroidism and renal osteodystrophy (CKD-MBD) in CKD Stage 3b–5 and dialysis (where failed kidneys lack 1-alpha-hydroxylase to convert plain Cholecalciferol into active 1,25-(OH)2-D3!); post-thyroidectomy / idiopathic hypoparathyroidism; severe hypocalcaemia prophylaxis prior to Denosumab in advanced CKD.

4. Therapeutic Indications & Evidence-Supported Uses

  • Secondary hyperparathyroidism and renal osteodystrophy (CKD-MBD) in CKD Stage 3b–5 and dialysis (where failed kidneys lack 1-alpha-hydroxylase to convert plain Cholecalciferol into active 1,25-(OH)2-D3!)
  • post-thyroidectomy / idiopathic hypoparathyroidism
  • severe hypocalcaemia prophylaxis prior to Denosumab in advanced CKD

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: CKD-MBD Secondary Hyperparathyroidism: Start 0.25 mcg PO Once Daily (or 0.25 mcg on alternate days if baseline calcium is high-normal); titrate every 4–8 weeks based on intact PTH (iPTH) and corrected Serum Calcium. Hypoparathyroidism: 0.5–2.0 mcg PO OD (alongside elemental Calcium 1000–2000 mg/day)

Administration & Meal Timing: May be taken with or without food | Morning or Bedtime (Once Daily or Thrice Weekly on dialysis days)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
Elimination & Renal Adjustment:
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment
Hepatic Impairment Considerations:
Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CRITICAL DISTINCTION FROM PLAIN CHOLECALCIFEROL (VITAMIN D3 60,000 IU): Calcitriol (0.25 mcg) and Alfacalcidol bypass renal 1-alpha-hydroxylase regulation and have a narrow therapeutic window — NEVER prescribe Calcitriol for simple nutritional Vitamin D deficiency in healthy patients (use Cholecalciferol 60,000 IU weekly x 8w instead!)! Contraindicated in hypercalcaemia (Ca2+ >10.2–10.5 mg/dL) and uncontrolled hyperphosphataemia

Key Clinical Precautions: Renal: Specifically indicated in CKD Stage 3b–5 when renal 1-alpha-hydroxylase fails. Hepatic: Prefer Calcitriol over Alfacalcidol in hepatic impairment

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Hypercalcaemia (30% if unmonitored!), hypercalciuria, hyperphosphataemia (Calcitriol increases intestinal absorption of BOTH calcium AND phosphate!)
  • Severe hypercalcaemia (thirst, polyuria, constipation, confusion, lethargy, pancreatitis, QTc shortening, arrhythmias, acute kidney injury), vascular and soft-tissue calcification (when Calcium x Phosphate product >55 mg2/dL2!)
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Thiazide diuretics (Chlorthalidone, HCTZ, Indapamide) decrease urinary calcium excretion and precipitate severe hypercalcaemia with Calcitriol!; Hypercalcaemia triggers fatal Digoxin arrhythmias!; Magnesium-containing antacids/laxatives + Calcitriol in dialysis = severe hypermagnesaemia; Cholestyramine/Sevelamer reduce absorption (space by >=2h)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: COUNTER SAFETY CHECK: Verify whether the doctor wrote 'Cholecalciferol' (nutritional Vit D3) or 'Calcitriol 0.25 mcg' (active kidney hormone Rocaltrol/Gemsoline); on Calcitriol, get a monthly blood calcium and phosphorus test, and report excessive thirst, frequent urination, constipation, or confusion immediately
  • Meal & Clock Timing Instruction: May be taken with or without food (Morning or Bedtime (Once Daily or Thrice Weekly on dialysis days))
  • Missed Dose Protocol: Take same day if remembered; never double dose
  • Geriatric Dispensing Pearl: Monitor serum calcium and renal function closely in older adults, especially if taking Calcium Carbonate or Thiazide diuretics

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Softgel Capsules: 0.25 mcg, 0.5 mcg, 1.0 mcg; Oral Drops; IV Injection: 1 mcg/mL

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 10 [10.14] (p. 133)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.